Amongst sufferers with relapsed or refractory follicular lymphoma (FL), the therapy mixture of Monjuvi (tafasitamab-cxix) plus Revlimid (lenalidomide) and Rituxan (rituximab) has been discovered to lead to a 57% discount within the threat of illness development or dying compared with placebo plus Revlimid and Rituxan, examine outcomes have proven.
Preliminary findings from the section 3 inMIND trial had been introduced on the 2024 American Society of Hematology (ASH) Annual Assembly and printed in Blood.
Within the examine, at a median follow-up of 14.1 months, the addition of Monjuvi to Revlimid and Rituxan resulted in what researchers described in Blood as a considerably decrease threat of development, relapse or dying versus therapy with placebo, with median progression-free survival occasions of twenty-two.4 months for the Monjuvi group in contrast with 13.9 months within the placebo group.
“Within the section 3 inMIND trial, [Monjuvi] demonstrated spectacular efficacy and security for treating sure sufferers with follicular lymphoma, the commonest sort of B-cell non-Hodgkin lymphoma,” stated Dr. Steven Stein, Chief Medical Officer of Monjuvi producer Incyte, in a information launch issued by the corporate. “These knowledge, the primary to judge the novel strategy of mixing CD19 and CD20 immunotherapies, present the potential of [Monjuvi] together with [Revlimid] and [Rituxan] to turn out to be a brand new normal of look after these sufferers. We stay up for working with regulatory authorities to probably convey this therapy ahead to sufferers with FL.”
Throughout the ASH convention, CURE® spoke with Dr. Christina Poh, a doctor on the Fred Hutch Most cancers Heart and an assistant professor within the Division of Hematology and Oncology, College of Washington Faculty of Drugs about how this mixture works to deal with most cancers.
Transcript:
By way of [Monjuvi] alone, [Monjuvi] is what we name an anti-CD19 monoclonal antibody. Primarily this drug targets CD19, which is a sign that’s discovered on the floor of most of the most cancers cells within the physique, like follicular lymphoma. As soon as this drug sees CD19, it binds to it, and that stimulates the immune system to come back to clear it up from the physique. [Rituxan] is basically one other monoclonal antibody, however that is anti-CD20, so it does the very same mechanism as [Monjuvi], however it targets CD20. [Revlimid] does quite a lot of issues, however the general considering is it modulates the immune system to assist these antibodies work higher in our physique.
Transcript has been edited for readability and conciseness.
Reference
“Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Outcomes from a Part 3 Examine (inMIND)” by Dr. Laurie H. Sehn et al., Blood.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
